Fused heterocyclic compounds

Details Fused heterocyclic compounds Fused heterocyclic compounds

2005-02-22

2005-02-22

Berch, Mark L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C549S070000

Reexamination Certificate

active

06858619

ABSTRACT:
Compounds useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor are provided that have the formula:whereinA and B are CR′;V is either a bond and W is —N(R″)—, or else V is —N(R″)— and W is a bond;Z is —N(R)—CH2—;R1, R2, R3, R4, R′, R″, and R are as defined herein;the subscript n is an integer from 0 to 8; and is a benzene ring.Pharmaceutical compositions and methods of using these compounds for the treatment and/or prevention of eating disorders, obesity, anxiety disorders and mood disorders, are also provided.

REFERENCES:
patent: 2001226269 (2001-08-01), None
patent: WO 9107966 (1991-06-01), None
patent: WO 9407896 (1994-04-01), None
patent: WO 9513071 (1995-05-01), None
patent: WO 9623793 (1996-08-01), None
patent: WO 9831684 (1998-07-01), None
patent: WO 200021577 (2000-04-01), None
patent: WO 200049046 (2000-08-01), None
patent: WO 200107606 (2001-02-01), None
patent: WO 200021169 (2001-03-01), None
patent: WO 200187834 (2001-11-01), None
patent: WO 200203070 (2002-01-01), None
patent: WO 200204433 (2002-01-01), None
patent: WO 200206245 (2002-01-01), None
patent: WO 2002002744 (2002-01-01), None
patent: WO 2002032897 (2002-04-01), None
patent: WO 2002051809 (2002-07-01), None
patent: WO 2002057233 (2002-07-01), None
patent: WO 2002076929 (2002-10-01), None
patent: WO 2002076947 (2002-10-01), None
patent: WO 2002083134 (2002-10-01), None
patent: WO 2002094799 (2002-11-01), None
patent: PCTUS02/13856 (2002-12-01), None
Langlois et al. (Tetrahedron Letters (1975), (11), 955-8.*
Bergman et al. Acta Chemica Scandinavica, Series B; Organic Chemistry and Biochemistry (1980), B (34)10, 763-6.*
Boutin et al. (Can. J. Physiol. Pharmacol. 80: 388-395 (2002).*
Chambers et al., “Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1”Nature,(1999) 400:261-65.
Gonzales et al., “Behavioral Effects of α-MSH and MCH After Cectral Administration in the Female Rat”,Peptides,(1996) 17:171-177.
Ishikura et al., “A Novel Entry to Pyrido [4,3-b] Carbazoles: An Efficient Synthesis of Ellipticine”, Chemical Abstracts (2000) 132:Abs #237230.
Monzon et al., “Response to novelty after i.c.v. injection of melanin-concentrating hormone (MHC) in rats”Physiol. Behav.(1999) 67:813-817.
Aceto, MD et al., “Dependence studies of new compounds in the Rhesus monkey, rat and mouse”, (1997) Department of Pharmacology and Toxicology, Medical College of Virginia Commonwealth University, pp. 363-407.
Blechert, S. et al., “Domino reactions—New concepts in the synthesis of indole alkaloids and other polycyclic indole derivatives”, (1995) Institut Für Organische Chemie, Sekr. C3, Technische Universität Berlin, Straβe des 17 Juni 135, D-10623 Berlin, Germany pp 592-604.
Fujii, H. et al., “A novel abnormal rearrangement in the fishcer indole synthesis”, (1997)Heterocycles45:2109-2112.
Gouyette, A. et al., “Synthesis, DNA intercalation and antitumor activity of 9-hydroxy-11-demethylellipticine and some derivatives. Comparison with the corresponding ellipticines”, (1980)Eur. J. Med. Chem.15:503-510.
Guillonneau, C. et al., “Synthesis of 9-O-substituted derivatives of 9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-α]carbazole-1-carboxylic acid (2-(dimethylamino)ethyl)amide and their 10-and 11-methyl analogues with improved antitumor activity”, (1990)J. Med. Chem.42:2191-2203.
Ishikura et al., “A Novel Entry to Pyrido [4,3-b] Carbazole: An Efficient Synthesis of Ellipticine”, Chemical Abstract, vol. 132, Abstract 237230, 2000.
Jones, RM et al., “6'-Guanidinonaltrindole, a highly selective and potent k-opioid receptor atagonist” (2000)Euro. J. Med. Chem.396:49-52.
Lipkowski, AW et al., “Benzomorphan alkaloids: natural peptidomimetics of opioid pharmacophores”, (1995)Letters in Peptide Science,2:177-181.
Olmsted, SL et al., “A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetic κ address element to the δ antagonist, naltrindole: 5'-[(N2-alkylamidino)methyl]naltrindole derivatives as a novel class of κ opioid receptor antagonists” (1993)J. Med. Chem.36:179-180.
Portoghese, PS et al., “Naltrindole 5'-isothiocyanate: a nonequilibrium, highly selective δ opioid receptor antagonist” (1990)J. Med. Chem.33:1547-1548.
Portoghese, PS et al., “Design of peptidomimetic δ opioid receptor antagonists using the message-address concept” (1990)J. Med. Chem.33:1714-1720.
Portoghese, PS et al., “Application of the message-address concept in the design of highly potent and selective non-peptide δ opioid receptor antagonists”, (1988)J. Med. Chem.31:281-282.
Portoghese, PS et al., “7'-substituted amino acid conjugates of naltrindole. Hydrophillic groups as determinants of selective antagonism of δ1opioid receptor-mediated antinociception in mice.” (1995)J. Med. Chem.38:402-407.
Serie G Chimie Organique.—Une nouvelle synthese du systeme 6 H-pyrido-(4.3b) carbaxolique, (1972)C.R. Acad. Sc. Parismt. 274:1948-1949.
Stevens, WC et al., “Potent and selective indolomorphinan antagonists of the kappa-opioid receptor”, (200)J. Med. Chem.43:2759-2769.
Saito et al., “Molecular characterization of the melanin-concentrating-hormone receptor”Nature,(1999) 400:265-69.
Saito et al., TEM (2000) 8:299-303.
Shimada et al., “Mice lacking melanin-concentrating hormone are hypophagic and lean” Nature, (1998) 396:670-74.

Affiliated with

Also associated with

Rating

Fused heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fused heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused heterocyclic compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3503604